• Publications
  • Influence
Mutational dynamics between primary and relapse neuroblastomas
TLDR
The mutational burden significantly increased in relapsing tumors, accompanied by altered mutational signatures and reduced subclonal heterogeneity and global allele frequencies at relapse indicated clonal mutation selection during disease progression.
Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.
TLDR
Data indicate that fusion protein-directed IL-2 therapy induces a T cell-dependent host immune response capable of eradicating established colon cancer metastases in an animal tumor model.
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
TLDR
An international, open-label, phase 3, randomised, controlled trial in patients with high-risk neuroblastoma, aiming to assess event-free survival after treatment with ch14.18/CHO (dinutuximab beta) and subcutaneous IL-2.
Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
TLDR
The data suggest that a study of ch14.18-IL-2 as an adjuvant treatment in patients with minimal residual disease may be of value, and targeted cytokine immunotherapy with a recombinant anti-GD2 antibody-interleukin 2 fusion protein elicits an effective antitumor response.
Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy.
TLDR
Data show that targeted delivery of cytokines to the tumor microenvironment offers a new strategy to elicit an effective cellular immune response mediated by NK cells against metastatic neuroblastoma.
NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
TLDR
Clonal derivatives of the clinically applicable human NK cell line NK‐92 are generated that stably express a GD2‐specific chimeric antigen receptor (CAR) comprising an anti‐GD2 ch14.18 single chain Fv antibody fusion protein with CD3‐ζ chain as a signalling moiety to combine specific antibody‐mediated recognition of NB cells with the potent cytotoxic activity of NK cells.
Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.
TLDR
A synergy between two novel monotherapies directed against vascular and tumor compartments, respectively, a tumor vasculature-specific antiangiogenic integrin alphav antagonist and tumor-specific antibody-interleukin 2 (IL-2) fusion proteins is reported.
Immunocytokines: a promising approach to cancer immunotherapy.
TLDR
Proof of concept was established, indicating that immunocytokine-induced activation and expansion of immune effector cells in the tumor microenvironment can effectively eradicate established tumor metastases.
Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies.
TLDR
The use of taurolidine citrate lock solution was associated with a significant reduction in bloodstream infection in immunocompromised paediatric patients and may prevent colonization of CVCs if used from the time of insertion, but not after a period of no-lock catheter use.
Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of MicroRNA-34a Using Anti-Disialoganglioside GD2 Coated Nanoparticles
TLDR
This work demonstrates the first silica nanoparticle-based targeted delivery of a tumor suppressive, pro-apoptotic microRNA, miR-34a, to neuroblastoma tumors in a murine orthotopic xenograft model, and highlights the potential of anti-GD2-nanoparticle-mediated targeted delivery in both the treatment of GD2-expressing tumors and as a basic discovery tool for elucidating biological effects of novel miRNAs on tumor growth.
...
1
2
3
4
5
...